Market Overview

European Conjugate Vaccine Market Analysis & Forecasts 2018-2023, With an Expected CAGR of 3.6% -


The "Europe
Conjugate Vaccine Market (2018-2023)"
report has been added to's

Conjugate vaccine is a type of vaccine that contains bacterial capsular
polysaccharide, attached with a protein to enhance immunogenicity and
protect against invasive diseases. Europe is a market with stable growth
for conjugate vaccines. The conjugate vaccine market in Europe is
expected to expand at a CAGR of 3.6% leading to a revenue of USD 8.94 Bn
by 2023. By volume, it is anticipated to reach 504.46 Million units by
2023, expanding at a CAGR of 3.7%.

Key growth factors:

The European market will not display any extraordinary growth but
average figures. Key growth factors include increasing emphasis on and
availability of funds for research and development. Moreover,
advancements in medical science, awareness about the availability of a
higher number of vaccines for diseases will drive the growth of this
market. Increasing vaccination programs by government, their
initiatives, and increase in research and development activities will
result in the growth of this market.

Threats and key players:

  • The Europe conjugate vaccine market is expected to grow at a steady
    pace. The scope for significant growth is limited. Vaccine shortages
    are a major problem which will hinder the growth of the market. The
    shortage of vaccines affecting some EU/EEA Member States had direct
    effects on the delivery of national vaccination programmes. Since
    2015, nine EU/EEA member states had to adjust their immunization
  • Major conjugate vaccine providers operating in the market are
    GlaxoSmithKline, Pfizer Inc., Merck, Novartis, Sanofi Pasteur, etc.

Companies Mentioned

  • GlaxoSmithKline
  • Pfizer Inc.
  • Merck & Co.
  • Novartis
  • Sanofi Pasteur
  • CSL Limited

Key Topics Covered:

Chapter 1: Executive summary

Chapter 2: Market overview

Chapter 3: Europe major segment overview - by disease indication

Chapter 4: Europe major segment overview - by end user

Chapter 5: EU5 - by disease indication

Chapter 6: EU5 - by end user

Chapter 7: Rest of EU - by disease indication

Chapter 8: Rest of EU - by end user

Chapter 9: Competitive landscape

For more information about this report visit

View Comments and Join the Discussion!